Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Sylvia DRAZILOVA"'
Autor:
Dominik Šafčák, Sylvia Dražilová, Jakub Gazda, Igor Andrašina, Svetlana Adamcová-Selčanová, Radovan Barila, Michal Mego, Marek Rác, Ľubomír Skladaný, Miroslav Žigrai, Martin Janičko, Peter Jarčuška
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3557-3570 (2023)
Hepatocellular carcinoma (HCC) has multiple molecular classes that are associated with distinct etiologies and, besides particular molecular characteristics, that also differ in clinical aspects. We aim to characterize the clinical aspects of alcohol
Externí odkaz:
https://doaj.org/article/8d822def4b264708af41d55763b3cd0b
Autor:
Pavol Kristian, Ivana Hockicková, Elena Hatalová, Daniela Žilinčanová, Marek Rác, Veronika Bednárová, Patrícia Denisa Lenártová, Sylvia Dražilová, Ľubomír Skladaný, Ivan Schréter, Peter Jarčuška, Monika Halánová
Publikováno v:
Viruses, Vol 15, Iss 8, p 1695 (2023)
Background: It is assumed that the prevalence of hepatitis D in HBsAg-positive individuals reaches 4.5–13% in the world and on average about 3% in Europe. Data from several European countries, including Slovakia, are missing or are from an older pe
Externí odkaz:
https://doaj.org/article/b6b1f7c4ff1d4998b7c0ad28c09b1727
Autor:
Sylvia Drazilova, Tomas Koky, Marian Macej, Martin Janicko, Dagmar Simkova, Ariunzaya Tsedendamba, Slavomira Komarova, Peter Jarcuska
Publikováno v:
Gastroenterology Insights, Vol 15, Iss 2, Pp 419-432 (2024)
In this review article, we summarize the most common clinical manifestations of Primary biliary cholangitis (PBC): pruritus, fatigue, osteoporosis, and dyslipoproteinemia and discuss their impact of the patients’ quality of life. More than half of
Externí odkaz:
https://doaj.org/article/9cc5e6aa9469492d93be44335f32cb71
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 17 (2024)
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease characterized by the destruction of the small intrahepatic bile ducts, which can progress to liver cirrhosis. The gold standard in the treatment of PBC is ursodeoxycholic a
Externí odkaz:
https://doaj.org/article/e9910144228f4fc18a263cf2337ac793
Autor:
Sylvia Drazilova, Eduard Veseliny, Patricia Denisa Lenartova, Dagmar Drazilova, Jakub Gazda, Ivica Grgurevic, Martin Janicko, Peter Jarcuska
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2021 (2021)
IgG4-related sclerosing cholangitis, a biliary manifestation of an IgG4-related disease, belongs to the spectrum of sclerosing cholangiopathies which result in biliary stenosis. It presents with signs of cholestasis and during differential diagnosis
Externí odkaz:
https://doaj.org/article/d320906d071c457e86f68c4cbb3fa7b6
Autor:
Jakub Gazda, Martin Janicko, Sylvia Drazilova, Ivica Grgurevic, Tajana Filipec Kanizaj, Tomas Koller, Beatrica Bodorovska, Maja Mijic, Ivana Mikolasevic, Ivana Knezevic Stromar, Branislav Kucinsky, Matej Gazda, Peter Jarcuska
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2021 (2021)
Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim.
Externí odkaz:
https://doaj.org/article/069badd8a34845328fd1dec40843f2b8
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2021 (2021)
Background. Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease with wide ranges of reported incidence and prevalence. Aim. To map the incidence and prevalence of PBC in European countries from 2000 through 2020. Metho
Externí odkaz:
https://doaj.org/article/42cd3ce3c6324e15b82d162977e6e69b
Autor:
Robert Flisiak, Dorota Zarębska-Michaluk, Egle Ciupkeviciene, Sylvia Drazilova, Sona Frankova, Ivica Grgurevic, Bela Hunyady, Peter Jarcuska, Limas Kupčinskas, Michael Makara, Gunita Saulite-Vanaga, Marieta Simonova, Jan Sperl, Ieva Tolmane, Adriana Vince
Publikováno v:
Viruses, Vol 14, Iss 3, p 482 (2022)
In 2016, the WHO announced a plan to eliminate viral hepatitis as a public health threat by 2030. In this narrative review, experts from Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia assessed the feasibility o
Externí odkaz:
https://doaj.org/article/73899e61351e4c9d9d7ca054a09abb60
Autor:
Sylvia Drazilova, Martin Janicko, Lubomir Skladany, Pavol Kristian, Marian Oltman, Maria Szantova, Dusan Krkoska, Eva Mazuchova, Lubica Piesecka, Veronika Vahalova, Marek Rac, Ivan Schreter, Ladislav Virag, Tomas Koller, Adriana Liptakova, Miriam Ondrasova, Peter Jarcuska
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2018 (2018)
Background and Aims. Chronic hepatitis C is a systemic disease and type 2 diabetes mellitus (T2DM) belongs to more common extrahepatic. The aim of this study was to (i) explore the prevalence of impaired fasting glucose (IFG) and T2DM in patients wit
Externí odkaz:
https://doaj.org/article/df33a1c69b4f4e7892e384221b2e50f3
Publikováno v:
Canadian Journal of Gastroenterology and Hepatology, Vol 2018 (2018)
Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people. Sustained viral response (SVR) achievement led to decreasing incidence and prevalenc
Externí odkaz:
https://doaj.org/article/5683313100f84aaa9c541bf70764481d